Bernhard Hampl
Description:
Dr. Hampl joined Great Point Partners’ Advisory Board in 2011 and is Co-Chairman of the Board of Directors our portfolio company Cytovance Biologics. He is also currently Executive Chairman of the Board of APP / Fresenius. Previously, Dr. Hampl was CEO of Eon Labs from 1996 to 2005 until the acquisition by Novartis at which time he became the CEO of the Sandoz US-division of Novartis. During the period he was CEO of Eon, its revenue grew from $20 million to $435 million. Dr. Hampl earned a Ph.D. in Pharmaceutical Chemistry from the Ludwig Maximilian University of Munich, Germany, School of Pharmacy.
Summary:
Dr. Hampl joined Great Point Partners’ Advisory Board in 2011 and is Co-Chairman of the Board of Directors our portfolio company Cytovance B...
Number of Registered Investments:1
Contact Details:
- Find the location here
- No email is provided
Find more here
Email is Not Provided
Updated August 2023. This content was crafted by an associate of Najafi Capital (“Najafi”) and is presented strictly for informational objectives. The details on this page neither advocate for nor dissuade the subscription, acquisition, or sale of any security or offering. The material Najafi evaluates for project owner screening and due diligence stems directly from the project owner presenting the investment opportunity. While Najafi perceives the information to have been sourced from trustworthy channels, there is no absolute assurance, warranty, or representation concerning its authenticity. Najafi renounces any liability regarding content provided by the project owner, inclusive of the data utilized to fulfill elements outlined on this page. Najafi is not accountable for the precision, legality, or the affirmation of subsequent details shared by the project owner.
Prospective investors are urged to perform their individual due diligence and authenticate the provided data. Investing inherently encompasses risks, inclusive of the potential loss of capital invested. All investors are recommended to ponder over these aspects in tandem with a chosen professional consultant to ascertain the suitability of an investment.